Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CCTL019H2301
Novartis Pharmaceuticals
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
1 trial -
CEXV811A12301
Novartis Pharmaceuticals
Immunoglobulin A Nephropathy (IgAN)
1 trial -
CFTY720D2311
Novartis Pharmaceuticals
Multiple Sclerosis
1 trial -
CJDQ443B12301
Novartis Pharmaceuticals
Advanced non-small cell lung cancer harboring the KRAS G12C mutation
1 trial -
CKJX839A12309
Novartis Pharmaceuticals
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.
1 trial -
CKJX839B12302
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease (ASCVD)
1 trial -
CKJX839C12303
Novartis Pharmaceuticals
Heterozygous Familial Hypercholesterolemia
1 trial -
CKJX839C12304
Novartis Pharmaceuticals
homozygous familial hypercholesterolemia
1 trial -
CKJX839D12303
Novartis Pharmaceuticals
Non-obstructive Coronary Artery Disease
1 trial -
CLEE011O12001
Novartis Pharmaceuticals
HR-positive HER-2- negative Breast Cancer
1 trial -
CLEE011O12301C
Novartis Pharmaceuticals
hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).
1 trial -
CLNP023A2301
Novartis Pharmaceuticals
IgA Nephropathy
1 trial -
CLNP023B12301
Novartis Pharmaceuticals
complement 3 glomerulopathy
1 trial -
CLNP023Q12301
Novartis Pharmaceuticals
generalized Myasthenia Gravis
1 trial -
CLOU064A2303B
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
CLOU064A2304
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
CLOU064C12301
Novartis Pharmaceuticals
Multiple Sclerosis
1 trial -
CLOU064C12302
Novartis Pharmaceuticals
Multiple Sclerosis
1 trial -
CLOU064C12306
Novartis Pharmaceuticals
Relapsing multiple sclerosis
1 trial -
CLOU064J12301
Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1 trial -
CLOU064J12302
Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1 trial -
CLOU064J12303B
Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1 trial -
CLOU064M12301
Novartis Pharmaceuticals
Chronic Inducible Urticaria (CINDU)
1 trial -
CLOU064O12301
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.